Dan McDonald

638 total citations
12 papers, 136 citations indexed

About

Dan McDonald is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dan McDonald has authored 12 papers receiving a total of 136 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dan McDonald's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Dan McDonald is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Dan McDonald collaborates with scholars based in United States, China and France. Dan McDonald's co-authors include Georgia Kollia, Ashok Gupta, Jon M. Wigginton, F. Stephen Hodi, Suzanne L. Topalian, Scott Antonia, Mario Sznol, Julie R. Brahmer, Scott Gettinger and David F. McDermott and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Biotechnology and Bioengineering.

In The Last Decade

Dan McDonald

12 papers receiving 132 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dan McDonald United States 9 90 57 37 22 15 12 136
Dristhi Ragoonanan United States 7 81 0.9× 43 0.8× 30 0.8× 15 0.7× 27 1.8× 23 144
Christine M. Minnar United States 6 96 1.1× 119 2.1× 49 1.3× 17 0.8× 10 0.7× 14 195
Florian Märkl Germany 4 97 1.1× 88 1.5× 29 0.8× 13 0.6× 12 0.8× 8 140
Siham Farhane France 6 105 1.2× 70 1.2× 25 0.7× 20 0.9× 16 1.1× 7 162
Shilpa Mankikar Canada 3 105 1.2× 78 1.4× 30 0.8× 15 0.7× 11 0.7× 9 151
Tana Omokoko Germany 5 90 1.0× 86 1.5× 54 1.5× 9 0.4× 23 1.5× 7 136
Emma Young Sweden 4 90 1.0× 96 1.7× 30 0.8× 9 0.4× 8 0.5× 6 188
Charles Mulligan United States 5 51 0.6× 65 1.1× 25 0.7× 15 0.7× 6 0.4× 5 127
Yaroslav Kaminskiy Russia 4 52 0.6× 38 0.7× 30 0.8× 7 0.3× 13 0.9× 5 90

Countries citing papers authored by Dan McDonald

Since Specialization
Citations

This map shows the geographic impact of Dan McDonald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan McDonald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan McDonald more than expected).

Fields of papers citing papers by Dan McDonald

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan McDonald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan McDonald. The network helps show where Dan McDonald may publish in the future.

Co-authorship network of co-authors of Dan McDonald

This figure shows the co-authorship network connecting the top 25 collaborators of Dan McDonald. A scholar is included among the top collaborators of Dan McDonald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan McDonald. Dan McDonald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Luke, Jason J., Robin Edwards, Cyrus V. Hedvat, et al.. (2018). Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. Annals of Oncology. 29. viii403–viii403. 2 indexed citations
3.
4.
Segal, Neil H., F. Stephen Hodi, Rachel E. Sanborn, et al.. (2014). A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). TPS3115–TPS3115. 10 indexed citations
5.
Sanborn, Rachel E., William H. Sharfman, Neil H. Segal, et al.. (2013). A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.. Journal of Clinical Oncology. 31(15_suppl). TPS3110–TPS3110. 12 indexed citations
6.
Topalian, Suzanne L., Julie R. Brahmer, F. Stephen Hodi, et al.. (2012). Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. Journal of Clinical Oncology. 30(18_suppl). CRA2509–CRA2509. 5 indexed citations
7.
McDermott, David F., Charles G. Drake, Mario Sznol, et al.. (2012). Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 30(15_suppl). 4505–4505. 10 indexed citations
8.
Brahmer, Julie R., Leora Horn, Scott Antonia, et al.. (2012). Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). 7509–7509. 21 indexed citations
9.
Hodi, F. Stephen, Mario Sznol, David F. McDermott, et al.. (2012). Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).. Journal of Clinical Oncology. 30(15_suppl). 8507–8507. 13 indexed citations
10.
Agrawal, Shruti, Feng Yan, Georgia Kollia, et al.. (2012). Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody.. Journal of Clinical Oncology. 30(15_suppl). TPS2622–TPS2622. 9 indexed citations
11.
Topalian, Suzanne L., Julie R. Brahmer, F. Stephen Hodi, et al.. (2012). Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. Journal of Clinical Oncology. 30(15_suppl). CRA2509–CRA2509. 12 indexed citations
12.
Bill, J, Hui Liu, Jun Liu, et al.. (2010). Increasing parvovirus filter throughput of monoclonal antibodies using ion exchange membrane adsorptive pre‐filtration. Biotechnology and Bioengineering. 106(4). 627–637. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dristhi Ragoonanan Breakdown of academic impact, for papers by Christine M. Minnar Breakdown of academic impact, for papers by Florian Märkl Breakdown of academic impact, for papers by Siham Farhane Breakdown of academic impact, for papers by Shilpa Mankikar Breakdown of academic impact, for papers by Tana Omokoko Breakdown of academic impact, for papers by Emma Young Breakdown of academic impact, for papers by Charles Mulligan Breakdown of academic impact, for papers by Yaroslav Kaminskiy
Rankless by CCL
2026